552 related articles for article (PubMed ID: 20381786)
1. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
2. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
Alkawas AA; Shahien EA; Hussein AM
J Glaucoma; 2010 Dec; 19(9):622-6. PubMed ID: 20179624
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
4. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
Lupinacci AP; Calzada JI; Rafieetery M; Charles S; Netland PA
Adv Ther; 2009 Feb; 26(2):208-16. PubMed ID: 19234680
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.
Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ
Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917
[TBL] [Abstract][Full Text] [Related]
7. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma.
Fakhraie G; Katz LJ; Prasad A; Eslami Y; Sabour S; Zarei R; Moghimi S
J Glaucoma; 2010 Mar; 19(3):212-8. PubMed ID: 19593201
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
Kotecha A; Spratt A; Ogunbowale L; dell'Omo R; Kulkarni A; Bunce C; Franks WA
Arch Ophthalmol; 2011 Feb; 129(2):145-50. PubMed ID: 21320957
[TBL] [Abstract][Full Text] [Related]
9. [Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases].
Douat J; Auriol S; Mahieu-Durringer L; Ancèle E; Pagot-Mathis V; Mathis A
J Fr Ophtalmol; 2009 Nov; 32(9):652-63. PubMed ID: 19892433
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
11. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.
Silva Paula J; Jorge R; Alves Costa R; Rodrigues Mde L; Scott IU
Acta Ophthalmol Scand; 2006 Aug; 84(4):556-7. PubMed ID: 16879583
[No Abstract] [Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Iliev ME; Domig D; Wolf-Schnurrbursch U; Wolf S; Sarra GM
Am J Ophthalmol; 2006 Dec; 142(6):1054-6. PubMed ID: 17157590
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
14. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma.
Ghosh S; Singh D; Ruddle JB; Shiu M; Coote MA; Crowston JG
Clin Exp Ophthalmol; 2010 May; 38(4):353-7. PubMed ID: 20665941
[TBL] [Abstract][Full Text] [Related]
15. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Mason JO; Albert MA; Mays A; Vail R
Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
[No Abstract] [Full Text] [Related]
16. Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma.
Chen CH; Lai IC; Wu PC; Chen YJ; Chen YH; Lee JJ; Liu YC; Kuo HK
J Ocul Pharmacol Ther; 2010 Feb; 26(1):111-8. PubMed ID: 20148654
[TBL] [Abstract][Full Text] [Related]
17. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
Higashide T; Murotani E; Saito Y; Ohkubo S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):603-10. PubMed ID: 22116499
[TBL] [Abstract][Full Text] [Related]
18. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.
Duch S; Buchacra O; Milla E; Andreu D; Tellez J
J Glaucoma; 2009 Feb; 18(2):140-3. PubMed ID: 19225351
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report.
Sothornwit N
J Med Assoc Thai; 2008; 91 Suppl 1():S162-5. PubMed ID: 18672609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
